Jehad Azar, MD
Pulmonary Disease · Phoenix, AZNPI 1447748397
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,286 of the $2,066 with a category attached, or 62.3%. Intuitive Surgical accounts for 81.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $997, more than ten times the $56 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in AZ, where the typical reported total is $2,499.
Across 18 payments — averaging $114.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Actelion Pharmaceuticals US, Inc.$211
- Insmed, Inc.$123
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15
- Amgen$14
- Pfizer$14
- plus $13 from 1 others
What the payments were for
- Travel & lodging$1,28662%
- Food & beverage$77938%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $1,676 |
| Actelion Pharmaceuticals US, Inc. | 4 | $211 |
| Insmed, Inc. | 1 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Amgen | 1 | $14 |
| Pfizer | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,493
- Arikayce$123
How this compares
$2,066 in reported general payments places this provider in the 45th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 41 | $522,806 |
| OpsumitMacitentan | 11 | $160,336 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $36,422 |
| Pirfenidone | 21 | $32,106 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,492 |
| DuleraMometasone/Formoterol | 21 | $7,684 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $6,556 |
| Mycophenolate Mofetil | 54 | $5,852 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,487 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,136 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $2,768 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,433 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,160 |
| Prednisone | 88 | $1,017 |
| Ipratropium Bromide | 17 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $211 | $160,33611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.